Please use this identifier to cite or link to this item:
https://hdl.handle.net/1959.11/21283
Title: | Commercial PCV2a-based vaccines are effective in protecting naturally PCV2b-infected finisher pigs against experimental challenge with a 2012 mutant PCV2 | Contributor(s): | Opriessnig, Tanja (author); Gerber, Priscilla Freitas (author) ; Xiao, Chao-Ting (author); Halbur, Patrick G (author); Matzinger, Shannon R (author); Meng, Xiang-Jin (author) | Publication Date: | 2014 | DOI: | 10.1016/j.vaccine.2014.06.004 | Handle Link: | https://hdl.handle.net/1959.11/21283 | Abstract: | Current commercial PCV2 vaccines are all based on PCV2a and have been shown to be effective in reducing PCV2a and PCV2b viremia and PCV2-associated lesions and disease. The recent emergence of novel mutant PCV2 (mPCV2) strains and linkage of mPCV2 with cases of porcine circovirus associated disease (PCVAD) in vaccinated herds have raised concerns over emergence of vaccine-escape mutants and reduced efficacy of PCV2a-based vaccines. The aim of this study was to determine the ability of three commercial PCV2a-based vaccines administered in the presence of an ongoing PCV2b infection and passively-acquired anti-PCV2 antibodies to protect conventional pigs against experimental challenge with mPCV2 at 11 weeks of age. Fifty naturally PCV2b-infected 2-week-old pigs were divided into five treatment groups with 10 pigs each. Pigs were unvaccinated (positive and negative controls) or vaccinated at 3 (VAC-A, VAC-B, VAC-C) and at 5 weeks of age (VAC-C). At 11 weeks of age, all pigs except the negative controls were challenged with a 2012 U.S. strain of mPCV2. The experiment was terminated 21 days after challenge. Under the conditions of this study, vaccinated pigs were protected against PCV2 viremia and lesions whereas non-vaccinated pigs were not. Moreover, concurrent PCV2b and mPCV2 infection was demonstrated in all positive controls and 3/10 had microscopic lesions consistent with PCVAD while negative controls infected with PCV2b alone did not develop PCVAD. The results indicate that concurrent PCV2b/mPCV2 infection can trigger PCVAD development and that commercial vaccines are effective in protecting conventional pigs against emerging mPCV2 strains. | Publication Type: | Journal Article | Source of Publication: | Vaccine, 32(34), p. 4342-4348 | Publisher: | Elsevier Ltd | Place of Publication: | United Kingdom | ISSN: | 1873-2518 0264-410X |
Fields of Research (FoR) 2008: | 070705 Veterinary Immunology 070706 Veterinary Medicine 070712 Veterinary Virology |
Fields of Research (FoR) 2020: | 300906 Veterinary immunology 300907 Veterinary medicine (excl. urology) 300914 Veterinary virology |
Socio-Economic Objective (SEO) 2008: | 830308 Pigs | Socio-Economic Objective (SEO) 2020: | 100410 Pigs | Peer Reviewed: | Yes | HERDC Category Description: | C1 Refereed Article in a Scholarly Journal |
---|---|
Appears in Collections: | Journal Article |
Files in This Item:
File | Description | Size | Format |
---|
SCOPUSTM
Citations
55
checked on Mar 9, 2024
Page view(s)
928
checked on Mar 9, 2023
Download(s)
2
checked on Mar 9, 2023
Items in Research UNE are protected by copyright, with all rights reserved, unless otherwise indicated.